Literature DB >> 2329110

Development of ciprofloxacin resistance in Brucella melitensis.

M B al-Sibai, S M Qadri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2329110     DOI： 10.1093/jac/25.2.302

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.

Authors:  M B al-Sibai; M A Halim; M M el-Shaker; B A Khan; S M Qadri
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  In vitro activities of six new fluoroquinolones against Brucella melitensis.

Authors:  I Trujillano-Martín; E García-Sánchez; I M Martínez; M J Fresnadillo; J E García-Sánchez; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

5.  The TolC homologue of Brucella suis is involved in resistance to antimicrobial compounds and virulence.

Authors:  Diana M Posadas; Fernando A Martín; Julia V Sabio y García; Juan M Spera; M Victoria Delpino; Pablo Baldi; Eleonora Campos; Silvio L Cravero; Angeles Zorreguieta
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

6.  Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.

Authors:  J A García-Rodríguez; J E García Sánchez; I Trujillano; E García Sánchez; M I García García; M J Fresnadillo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.